Market News
Smart Trading. Simplified.
Profit-Stocks: Upstart Gold Firm Hits High-Grade Gold Zone
In the gold sector, it's the tiny, low-priced exploration firms that typically make the initial discovery through drilling. It's also where investors can secure 10-fold and even 20-fold gains as early drill results are released to the public. Investors are currently jumping into this low-priced gold driller that just hit a high-grade discovery hole in Canada with additional results due any day.
Is It Too Late to Buy Moderna Stock?
Moderna Inc (NASDAQ:MRNA) is a Massachusetts-based biotechnology company that created the mRNA-1273 vaccine for COVID-19. This made it one of the most talked about pandemic stocks, and the implications of messenger RNA treatments extend far beyond this one virus. But now that it’s valued over $60 billion, is it too late to buy Moderna stock? […]
Former Broker Dealer Teaches Traders...
"If I had a stadium filled with my former students, I'd teach them how to spot and trade within Vomma Zone."
Don Kaufman, 23-Year Professional Trader and Educator at TD Ameritrade, shares it all.
Join Don as he breaks down this special zone he calls the "Vomma Zone."
Watch him share the exact playbook he uses to extract consistent profits from an increasingly volatile market.
5 Safe Stocks That You Can Leave To Your Children
Safe Stocks That You Can Leave To Your Children: When you spend a lifetime building your wealth, you don’t want that work to go to waste. Your goal is to leave your children with a sense of financial security. Perhaps your efforts will help them avoid some of the challenges you faced. They can retire […]
Capitalize on the EV Boom with this Top-Stock below $1 Per Share
The Electric Vehicle boom is here. We could see over 300 million EVs on the road by the end of the next decade. And individual investors - just like you - are cashing-in. The Smart Money is going straight to the source by investing in under-the-radar lithium mining stocks like this one: Developing one of the only lithium projects on US soil and currently trading below US$1 per share.
Will Lemonade Stock Recover?
Will Lemonade Stock Recover? Lemonade stock took a drubbing last week after the insurance company released a mixed-bag of news in its first quarter earnings report. Next day trading saw a loss of 18.5% on the company’s share price, dropping from $74.1 to $63.2. But why did the market turn so aggressively against a business […]
Get FREE Trade Alerts from Top Stock Research Firm (No Credit Card Needed)
Ken Berman, founder of Gorilla Trades, has announced that Gorilla Trades will offer 30 days of FREE trade alerts to investors around the world. "I believe retail investors can manage their own money if they use a proven trading system like mine. Once they see how easy it is, they will be hooked," he said. The daily alerts will be given using the Breakout Scanner, software Ken used to turn $250,000 into $5,000,000.
Is BioHaven Pharma Stock A Buy?
Is BioHaven Pharma Stock A Buy? By and large, the world of medicine depends on innovation. Any good doctor, researcher, or pharmaceutical company exists in a constant state of discovery, searching for the next revolutionary treatment or drug to help better the human race. We’ve seen this kind of innovation lately with the various COVID-19 […]
Investors Get Green-Light on US$0.25 Per Share Uranium Stock
Uranium prices are on a tear amid global mine shutdowns in the face of the coronavirus pandemic which has now forced nearly 50% of global uranium production offline. Select US uranium stocks are poised to deliver big gains to investors. Here's a little-known company that has quietly amassed over 45 million lbs of high-grade uranium resources - all on US soil - and trading below US$0.25 per share.
5 Stocks With Low Price to Free Cash Flow
Stocks With Low Price to Free Cash Flow: Price to free cash flow is a common method of estimating whether a company is valued too high or low. The metric is used because it helps to understand a company’s assets, liquidity, and revenue. Price to free cash flow can be manipulated on financial statements by […]
Small Biotech Could Soar 1,000%
There's no sector poised to deliver bigger gains in 2021 than small-cap biotech stocks.
In the past year alone...
Novavax Inc jumped from $6.26 to $270.51, a gain of 3,396%.
Aclaris Therapts jumped from $0.70 to $24.28 an increase of 1,583%.
Vaxart Inc rocketed from $0.97 to $14.94, a 1,083% jump.
Here's the next biotech we think could soar 1,000% >>>
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
PO Box 126
Catasauqua, PA 18032
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment